Lakefront Biotherapeutics Common Stock

Lakefront Biotherapeutics's common stock stands at $290M as of March 2026. That compares with $290M in the prior-year period — up 0.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Lakefront Biotherapeutics reported $290M in common stock versus $290M a year earlier — essentially flat versus a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $290M in the prior-year period — up 0.0% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Lakefront Biotherapeutics's common stock evolved across reporting periods, while the comparison chart places GLPG.AS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, common stock is commonly used to spot outliers. Lakefront Biotherapeutics's reading of $290M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.